RxDoctor Payments Data

Raju Abraham, MD

Pulmonary Disease · Kankakee, ILNPI 1003830852

Payments from drug & device makers

$27,570in general payments, 2019–2025

Across 663 payments — averaging $41.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$12K
  • Pulmonx Corporation$4K
  • GSK$2K
  • AstraZeneca$2K
  • Jazz Pharmaceuticals Inc.$1K
  • Covidien LP$936
  • plus $7K from 42 others

What the payments were for

  • Consulting fees$2,2508%
  • Travel & lodging$2,95311%
  • Food & beverage$11,90143%
  • Education$10,46738%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,570 in reported general payments places this provider in the 85th percentile of 539 pulmonary disease providers in Illinois.

See all pulmonary disease providers in Illinois

Medicare billing

Part B allowed, 2024
$325,861
Medicare patients
1,111
Services billed
3,381

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter358$326,145
Breo ElliptaFluticasone/Vilanterol412$235,243
OfevNintedanib Esylate12$158,232
AdempasRiociguat11$157,888
Breztri AerosphereBudesonide/Glycopyr/Formoterol147$131,537
Fasenra PenBenralizumab22$131,223
Spiriva RespimatTiotropium Bromide72$71,589
Incruse ElliptaUmeclidinium Bromide94$62,322
EliquisApixaban37$47,513
SymbicortBudesonide/Formoterol Fumarate81$33,553
Stiolto RespimatTiotropium Br/Olodaterol Hcl33$33,090
Arnuity ElliptaFluticasone Furoate68$28,522
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr42$27,620
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate77$22,700
Spiriva HandihalerTiotropium Bromide20$20,553

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta, Anoro Ellipta$1,906$679,852974 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Jardiance$858$278,951128 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,678$165,090228 claims
PfizerEliquis$46$47,51337 claims
MerckDulera, Asmanex$59$18,56656 claims
NovartisEntresto$142$16,52620 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$21$3,66212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 539 pulmonary disease providers in Illinois.

Other pulmonary disease in Kankakee

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →